Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: An EORTC New Drug Development Group StudyDUFFAUD, F; BORNER, M; FUMOLEAU, P et al.European journal of cancer (1990). 2004, Vol 40, Num 18, pp 2748-2752, issn 0959-8049, 5 p.Article

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumoursDE JONGE, M. J. A; DUMEZ, H; VERWEIJ, J et al.European journal of cancer (1990). 2006, Vol 42, Num 12, pp 1768-1774, issn 0959-8049, 7 p.Article

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC-New Drug Development GroupGIACCONE, G; SMIT, E. F; BACHMANN, P et al.European journal of cancer (1990). 2004, Vol 40, Num 5, pp 667-672, issn 0959-8049, 6 p.Article

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancerCLAMP, A. R; SCHOFFSKI, P; JAYSON, G. C et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 4, pp 579-585, issn 0344-5704, 7 p.Article

The EORTC and drug developmentLACOMBE, D; FUMOLEAU, P; ZWIERZINA, H et al.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 4, pp S19-S23, issn 1359-6349Article

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiformeVAN DEN BENT, M. J; GRISOLD, W; CARPENTIER, A. F et al.Annals of oncology. 2003, Vol 14, Num 12, pp 1732-1734, issn 0923-7534, 3 p.Article